Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 4:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 434 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Cannabinoids Clear all

Conditions: Cannabis, Drug Effects, Driving Performance
Interventions: 5 mg Dronabinol (Marinol®) + Placebo Beverage, 10 mg Dronabinol (Marinol®) + Placebo Beverage, 5 mg Dronabinol (Marinol®) + Alcohol Beverage, 10 mg Dronabinol (Marinol®) + Alcohol Beverage, Placebo Capsule + Alcohol Beverage, Placebo Capsule + Placebo Beverage; Drug
Lead sponsor: Food and Drug Administration (FDA); Federal
Eligibility: 21 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: West Bend, Wisconsin

Conditions: Epilepsy
Interventions: Cannabidiol; Drug
Lead sponsor: University of Utah; Other
Eligibility: 2 Years to 25 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy
Interventions: cannabidiol, Placebo; Drug
Lead sponsor: Castleton University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Castleton, Vermont

Conditions: Alcohol Use Disorder
Interventions: Cannabidiol; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 16 Years to 22 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Rett Syndrome, RTT
Interventions: GWP42003-P; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 14
States / cities: Birmingham, Alabama • La Jolla, California • Aurora, Colorado + 11 more

Conditions: Prader-Willi Syndrome
Interventions: CBDV Compound, Placebo; Drug
Lead sponsor: Eric Hollander; Other
Eligibility: 5 Years to 30 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Psoriasis
Interventions: Capsaicin; Drug
Lead sponsor: Wake Forest University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Perimenopause, Menopause
Interventions: Active Cannabinoid Product, Placebo; Dietary Supplement · Other
Lead sponsor: Washington State University; Other
Eligibility: 40 Years to 60 Years · Female only
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Pullman, Washington

Conditions: Opioid Withdrawal, Opioid Craving, Opioid Use Disorder
Interventions: Epidiolex, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Epilepsy, Dravet Syndrome
Interventions: GWP42003-P 20 mg/kg/day Dose, Placebo control; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 13
States / cities: Miami, Florida • Orlando, Florida • Atlanta, Georgia + 10 more

Conditions: Seizures
Interventions: Cannabidiol Oral Solution; Drug
Lead sponsor: INSYS Therapeutics Inc; Industry
Eligibility: 1 Year to 18 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 11
States / cities: San Francisco, California • Miami, Florida • Pensacola, Florida + 8 more

Conditions: Non-metastatic Bladder Cancer
Interventions: Cannabigerol; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Cannabis Dependence, Cannabis Withdrawal
Interventions: rimonabant, placebo; Drug
Lead sponsor: The Scripps Research Institute; Other
Eligibility: 21 Years to 30 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Epilepsy
Interventions: cannabidiol, Blood Test; Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 2 Years to 16 Years
U.S. locations: 2
States / cities: Gainesville, Florida • Miami, Florida

Conditions: Marijuana Abuse
Interventions: Tetrahydrocannabinol; Drug
Lead sponsor: Wayne State University; Other
Eligibility: 21 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Measuring THC-induced Cognitive Impairment Using a Mobile Application
Interventions: Dronabinol, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 35 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cannabidiol, Drug Induced Liver Injury, Drug Interaction
Interventions: Cannabidiol, Placebo, Citalopram, Morphine; Drug
Lead sponsor: Food and Drug Administration (FDA); Federal
Eligibility: 18 Years to 55 Years
Enrollment: 241 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: PTSD, Post Traumatic Stress Disorder, Suicide, Cannabis Use
Interventions: Cannabidiol (CBD) only, Placebo only, Delta-9-tetrahydrocannabinol (THC) only, THC:CBD 1:1; Drug
Lead sponsor: Leslie Lundahl; Other
Eligibility: 18 Years to 60 Years
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Epilepsy, Dravet Syndrome
Interventions: GWP42003-P, Placebo Control; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 23
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 20 more

Conditions: Sleep Disturbance
Interventions: Cannabidiol oral solution, Inert sesame seed oil; Drug
Lead sponsor: Mariana Cherner, PhD; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: San Diego, California

Conditions: Differential Female Response to Δ9-tetrahydrocannabinol (THC)
Interventions: Dronabinol, dextrose; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cannabinoid Hyperemesis Syndrome
Interventions: Haloperidol; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pain, Abuse, Drug, Intoxication; Cannabinoids
Interventions: Cannabis, Dronabinol, Smoked Placebo, Oral Placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 65 Years
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Motivation
Interventions: Study Product, THC Product, Placebo; Behavioral
Lead sponsor: Phylos Bioscience, Inc.; Industry
Eligibility: 21 Years to 100 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Clinical Study to Evaluate the Effects of Oral Delta-9-tetrahydrocannabinol (Δ9-THC) With and Without Alcohol on Perception and Driving Performance in Healthy Adults

Cannabidiol (CBD) to 27 Patients (Aged 2 Years - 19 Years) With Drug Resistant Epilepsy

Cannabidiol and Autonomic Function at Rest

Cannabidiol in Youth Alcohol Use Disorder

A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome

CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS)

Effects of Capsaicin on the Structure, Distribution, and Function of Cutaneous Small Nerve Fibers in Psoriatic Skin

Impact of Cannabinoids on Menopause Symptoms

Oral Cannabidiol for Opioid Withdrawal

Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)

Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder

The Effects of Cannabis on Post Operative Recovery After Radical Cystectomy

Clinical and Neurobiological Effects of Cannabis Dependence in Young Adults

Treatment of Drug Resistant Epilepsy

Responses to Marijuana-Related Cues Versus Neutral Cues in Adults Taking Tetrahydrocannabinol (THC) - 2

Developing a Mobile Method to Measure THC-induced Impairment

Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions

Wayne State Warriors Marijuana Clinical Research Program: Cannabinoid Adjunct to Prolonged Exposure & Recovery

GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome

CBD for Sleep in People With HIV

Individual Differences in Drug Response

Haloperidol For Outpatient Symptom Management in Patients Diagnosed With Cannabinoid Hyperemesis Syndrome in the Emergrency Department

Age-dependent Effects of Smoked and Oral Delta-9-THC

A Direct-to-Consumer Study Investigating the Effect of Specific Cannabinoid Products on Motivation, Energy Level, Focus, and Appetite in Healthy Adults